Norway - Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry

Since 2014, Norway Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry was up 0.1% year on year. In 2019, the country was ranked number 28 comparing other countries in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry at $36,963,598.93 Million PPP. Norway is overtaken by Greece, which was number 27 at $83,431,205.22 Million PPP and is followed by Chile with $28,786,954.1 Million PPP. United States ranked the highest with $70,565,318,932.39 Million PPP in 2019, that is an increase of 3.3% versus 2018. China, Japan and Germany respectively ranked number 2, 3 and 4 in this ranking. Iceland recorded the best 5 years average growth at +43.9% per year, while Lithuania witnessed the worst performance at -42.6% per year.

Loading...

Date Million US Dollars PPP
2019 36,963,598.93
2018 37,760,935.15
2017 40,809,121.46
2016 35,457,833.91
2015 33,253,265.38
Download all data from 1987 to 2019

How does Norway rank in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry?

# 69 Countries Million US Dollars PPP Last YoY 5‑years CAGR
1 #1
United States
70,565,318,932.39 2019 +3.3 % +4.5 % View data
2 #2
China
13,956,388,273.35 2019 +4.5 % +6.1 % View data
27 #27
Greece
83,431,205.22 2019 +0.1 % +0.1 % View data
28 #28
Norway
36,963,598.93 2019 -2.1 % +0.1 % View data
29 #29
Chile
28,786,954.10 2015 +2.7 % +15.9 % View data
Compare all 69 countries

Go Top